Front Panel Painting “LIFE” By William T Chua MD

More documents

Recommendations

Info

ecommend aspirin for primary prevention in lower risk individuals with diabetes, such as men
19. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995;75:894-903. 20. United Kingdom Prospective Study (UKPDS) 33. Lancet 1998:352;837-853. 21. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-259. 22. Executive Summary: Standards of Medical Care in Diabetes-2010. Diabetes Care, Volume 33, Supplement 1, January 2010. 23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-65. 24. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837-53. 25. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007; 298:1180-8. 26. Lindholm LH, Ibsen H. Dahlof B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002;359:1004-1010. 27. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72. 28. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 3;290(21):2805-16. 29. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert <strong>Panel</strong> on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment <strong>Panel</strong> III). JAMA 2001;285:2486-2497. 30. Cooper-DeHoff RM, Gong Y, Handberg EM, et al.. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 7;304(1):61-8. 31. Collins R, Armitage J, Parish S, et al. For the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-2016. 32. Colhoun HM, Betteridge DJ, Durnington PN, et al; for CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 2004;364:685-696. 33. Gaede P, Vedel P, Larsen N, Jensen GV, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 Diabetes. N Engl J. Med. 2003; 348:383-393. 34. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-89. 35. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22. Primary & Secondary Prevention 39
Page 2 and 3: Front Panel Painting: “LIFE” By
Page 4 and 5: Copyright © 2011 by the Stroke Soc
Page 6 and 7: Chapter IV. Guidelines for Transien
Page 8 and 9: MESSAGE from the PRESIDENT Since th
Page 10 and 11: WORLD STROKE DAY PROCLAMATION Cape
Page 12 and 13: ACTIVELY ENGAGE THE PUBLIC AROUND T
Page 14 and 15: An Overview of Stroke Overview Stro
Page 16 and 17: Overview The Cincinnati Prehospital
Page 18 and 19: Overview However, studies worldwide
Page 20 and 21: Overview Unique to this stroke hand
Page 22 and 23: Overview VI. CLINICAL STROKE SYNDRO
Page 24 and 25: Overview Posterior Cerebral Artery
Page 26 and 27: Overview VII. INCREASING THE YIELD
Page 28 and 29: Overview Strategies for preventing
Page 30 and 31: Overview workshops and helps suppor
Page 32 and 33: PREFACE TO THE GUIDELINES ON PRIMAR
Page 34 and 35: Diet modification encouraging low s
Page 36 and 37: C.2. Secondary Stroke Prevention Pr
Page 38 and 39: 3 compared to patients without stro
Page 40 and 41: Primary & Secondary Prevention Sub-
Page 44 and 45: Primary & Secondary Prevention 36.
Page 46 and 47: Bibliography Primary & Secondary Pr
Page 48 and 49: Primary & Secondary Prevention 3) A
Page 50 and 51: Primary & Secondary Prevention The
Page 54 and 55: Furthermore, low cholesterol is com
Page 56 and 57: Primary & Secondary Prevention Bibl
Page 58 and 59: Primary & Secondary Prevention VII.
Page 60 and 61: Primary & Secondary Prevention 2) A
Page 64 and 65: Primary & Secondary Prevention 4) M
Page 66 and 67: Primary & Secondary Prevention Loca
Page 70 and 71: Studies also suggest a dose respons
Page 72 and 73: Primary & Secondary Prevention 6. R
Page 74 and 75: Primary & Secondary Prevention 7. B
Page 76 and 77: Primary & Secondary Prevention The
Page 78 and 79: DEFINITION of TERMS Primary & Secon
Page 80 and 81: Primary & Secondary Prevention 6. T
Page 82 and 83: Primary & Secondary Prevention Andr
Page 88 and 89: Food group Allowed Restricted/avoid
Page 90 and 91: Primary & Secondary Prevention III.
Page 92 and 93:
Reviewed and Approved by the Philip
Page 94 and 95:
Acute Stroke Treatment I. SSP CLASS
Page 96 and 97:
Acute Stroke Treatment Delayed Mana
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Acute Stroke Treatment Avoid Hypogl
Page 106 and 107:
Acute Stroke Treatment 12. Hurtado
Page 108 and 109:
D. ADMINISTRATION of rt-PA to ACUTE
Page 110 and 111:
Acute Stroke Treatment • CT scan
Page 112 and 113:
Ancillary care for patients receivi
Page 114 and 115:
4. Use the following locally availa
Page 116 and 117:
B. Blood pressure Management in Acu
Page 118 and 119:
3. Control seizures if present. May
Page 120 and 121:
VIII. HEMICRANIECTOMY FOR MALIGNANT
Page 122 and 123:
Indications for EMERGENT HEMICRANIE
Page 124 and 125:
2.Optimal medical therapy including
Page 126 and 127:
Acute Stroke Treatment 8. Vahedi K,
Page 128 and 129:
Acute Stroke Treatment Items 2. Bes
Page 130 and 131:
Fig. 2: Dysarthria Ask the patient
Page 132 and 133:
I. TRANSIENT ISCHEMIC ATTACK Compar
Page 134 and 135:
Sim pl e an d co m plex partial s e
Page 136 and 137:
Many clinical trials have demonstra
Page 138 and 139:
2010 ASA/AHA Recommendations for An
Page 140 and 141:
TIA and AF Drug Trial Design Result
Page 142 and 143:
Drug Trial Design Result European S
Page 144 and 145:
TIA and AF 3. Antithrombotic Triali
Page 146 and 147:
Table 3: CHA DS VASC score and Stro
Page 148 and 149:
Table 5: Guidelines in achieving th
Page 150 and 151:
Limitations of Warfarin and Alterna
Page 152 and 153:
TIA and AF 7. Fuster V et al. ACC/A
Page 154 and 155:
Hemorrhagic Stroke INTRACRANIAL HEM
Page 156 and 157:
I. HYPERTENSIVE INTRACEREBRAL HEMOR
Page 158 and 159:
Hemorrhagic Stroke 3. Zubkov AY, Ma
Page 160 and 161:
Hemorrhagic Stroke 1. Hunt and Hess
Page 162 and 163:
2. Triple-H Therapy (e.g. volume ex
Page 164 and 165:
Hemorrhagic Stroke 19. Lysakowski C
Page 166 and 167:
enefits of treatment must be carefu
Page 168 and 169:
SPETZLER-MARTIN AVM GRADING SYSTEM
Page 170 and 171:
Bibliography 1. Ogilvy CS, Stieg PE
Page 172 and 173:
NEUROIMAGING IN ACUTE STROKE STROKE
Page 174 and 175:
Fig. 3: Hyperdense Middle Cerebral
Page 176 and 177:
area shown as an increase in MTT. C
Page 178 and 179:
MRI can demonstrate the penumbra or
Page 180 and 181:
The accumulated values for each of
Page 182 and 183:
The detection of intracerebral hema
Page 184 and 185:
T1TSE T2TSE GRE Fig. 13: Late subac
Page 186 and 187:
B. Intracerebral Hemorrhage • CT
Page 188 and 189:
Bibliography 1. de Lucas EM, Sanche
Page 190 and 191:
I.1. THE STROKE CENTER I. GUIDELINE
Page 192 and 193:
Stroke Unit Nurse-Rehab E.2. Delaye
Page 194 and 195:
2. Personnel with special interest
Page 196 and 197:
Stroke Unit Nurse-Rehab GENERAL OBJ
Page 198 and 199:
GENERAL OBJECTIVES SPECIFIC OBJECTI
Page 200 and 201:
Stroke Unit Nurse-Rehab GENERAL OBJ
Page 202 and 203:
COMPETENCY STATEMENTS FOR THE STROK
Page 204 and 205:
C. General Supportive Care of Strok
Page 206 and 207:
Stroke Unit Nurse-Rehab Course Obje
Page 208 and 209:
Stroke Unit Nurse-Rehab METHODOLOGY
Page 210 and 211:
Stroke Unit Nurse-Rehab 206 • Fiv
Page 212 and 213:
6. Physical fitness training • Ga
Page 214 and 215:
E. Dysphagia and Swallowing All pat
Page 216 and 217:
I. ACUTE POST-STROKE REHABILITATION
Page 218 and 219:
Reassessment of Rehabilitation Prog
Page 220 and 221:
Assessment of Discharge Environment
Page 222 and 223:
LEVELS OF STROKE CARE STROKE CENTER
Page 224 and 225:
5th Edition SSP Handbook WORKING CO
Page 226 and 227:
STROKE SOCIETY OF THE PHILIPPINES B
Page 228 and 229:
SSP CORPORATE MEMBERS United Labora
show all

Front Panel Painting “LIFE” By William T Chua MD

Create successful ePaper yourself

Delete template?

Save as template?